Higher doses of liraglutide (1.2 and 1.8 mg), which were administered over 12 weeks in C-peptide-negative and overweight persons with T1D, were associated with a modest reduction in mean glucose levels and insulin doses, as well as significant weight loss [64]. This evidence concerns the gene INS and type 1 diabetes mellitus.